Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Withdrawn 3Completed 3Terminated 2Unknown 1Suspended 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × duvelisib × Clear all
NCT04331119 2026-05-06

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Washington University School of Medicine

Phase 2 Terminated
17 enrolled
Lymphoid

Lymphoma, T-Cell

NCT04209621 2022-03-09

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡